AptarGroup Inc. reported third quarter 2025 results with reported sales increasing 6.0% to $961 million compared to $909 million in the prior year quarter. Core sales increased 1.0%. Reported net income rose 28.0% to $128 million, and reported earnings per share increased 30.0% to $1.92. Segment results for the quarter show reported sales growth of 6.0% for Pharma, 8.0% for Beauty, and 1.0% for Closures. Currency effects reduced total reported sales by 4.0%. The Beauty segment's sales increase was driven by a 4.0% benefit from currency changes and a 4.0% contribution from acquisitions, while core sales remained flat. The company reported strong product volume growth in Closures and Pharma, particularly in injectables and nasal products in Europe, while Beauty experienced mixed market performance. For the nine months ended September 30, 2025, reported earnings per share were $4.75, up 17.0% from $4.05 a year ago. Adjusted earnings per share for the period were $4.48, a 7.0% increase from $4.19 in the prior year at comparable exchange rates. The reported effective tax rate was 20.4% and the adjusted effective tax rate was 21.9%. Free cash flow for the first nine months was $206 million, with a year-over-year decline attributed to higher working capital and pension contributions, partially offset by lower capital expenditures. The company ended September with $265 million in cash and short-term investments and $936 million in net debt.